Rivaroxaban reduces VTE among ambulatory patients with pancreatic cancer

CHICAGO — Rivaroxaban thromboprophylaxis greatly reduced venous thromboembolism among ambulatory patients with pancreatic cancer, according to results of a prespecified subgroup analysis of the CASSINI study presented at ASCO Annual Meeting.
Researchers observed no increase in major bleeding during the intervention period.
“Pancreatic cancer is a known very high-risk malignancy associated with venous thromboembolism and, in fact, by itself, has been the subject of two prior randomized trials,” Alok A. Khorana, MD, professor of medicine at Cleveland Clinic Lerner College of

Source link

Related posts

Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice


Intestinal autophagy links psychosocial stress with gut microbiota to promote inflammatory bowel disease


FDA: Illnesses Tied to Fresh Crab Meat Imported From Venezuela


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World